RAPT Therapeutics RAPT 深 滬
已收盤 09-12 16:00:00 美东时间
16.22
+0.520
+3.31%
華盛通- 最 高16.59
- 今 開15.63
- 成交量 34.03万股
- 最 低 15.4341
- 昨 收 15.70
- 總市值 2.68亿
- 52周最高 26.56
- 市盈率 靜 --
- 換手率 2.06%
- 52周最低 5.6656
- 委 比 -78.97%
- 總股本 1653.78万
- 歷史最高 409.68
- 量 比 3.39
- 振 幅 7.36%
- 歷史最低 5.6656
- 每 手 1
- 風險率 3.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics announced that its management will participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, focused on developing precision medicines for neurological and psychiatric disorders, will host a fireside chat during the virtual event. Investors can access the webcast on the company’s website. Rapport’s RAP technology platform enables the creation of targeted sma...
09-11 20:05
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Rapport Therapeutics announced that its Phase 2a trial of RAP-219 for drug-resistant focal onset seizures met primary endpoints with high statistical significance, showing a 77.8% reduction in clinical seizures and 24% achieving seizure freedom. The drug was well-tolerated, with mild side effects observed in most patients. The company plans to advance RAP-219 into Phase 3 trials in late 2026 and host a conference call to discuss the results.
09-08 10:00
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics将举行电话会议和网络直播，于9月8日上午8点ET，公布RAP-219治疗难治性局灶性癫痫的IIa期顶线结果。公司聚焦神经及精神疾病精准药物，RAP技术基于受体蛋白，使药物如RAP-219精准作用于大脑特定区域，用于治疗癫痫、双相情感障碍和神经痛等。
09-05 20:05
Wells Fargo Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $38
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $51 to $38.
08-08 23:32
RAPT Therapeutics GAAP EPS of -$0.65
RAPT Therapeutics press release (NASDAQ:RAPT): Q2 GAAP EPS of -$0.65. As of June 30, 2025, the Company had cash and cash equivalents and marketable securities of $168.9 million. More on RAPT Therape...
08-07 21:20
RAPT Therapeutics Q2 EPS $(0.65) Misses $(0.63) Estimate
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 2.69 percent. This is a 88.58 percent increase over losses of $(5.69) per share
08-07 20:06
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
LifeSci Capital Initiates Coverage On RAPT Therapeutics with Outperform Rating, Announces Price Target of $31
LifeSci Capital initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Outperform rating and announces Price Target of $31.
07-23 05:08
